

DRIEHAUS CAPITAL MANAGEMENT LLC

Driehaus Event Driven Fund Portfolio

as of 10/31/2016

Security Name

ACLARIS THERAPEUTICS	COM
ALTICE NV	EURO.01 (COMMON SHAR
AMC ENTMT HLDGS INC	CL A COM
APOL 01/20/17 P8	APOLLO ED GROUP INC
APOLLO EDUCATION	GROUP INC
BLUEPRINT MEDICINES	COM
BOK FINL CORP	COM NEW
CARMIKE CINEMAS INC	
CSRA INC	COM
DEPOMED INC	COM
ENDURANCE INTL	BANKDEBT 02/09/2023
EUR FORWARD	CONTRACT 12/01/16
EURO CURRENCY	
FAIRPOINT COMMUNICAT	COM
FLEXION THERAPEUTICS	COM
FNF GROUP	
GAMING & LEISURE PPT	COM
GBP FORWARD	CONTRACT 12/01/2016
GBP FORWARD	CONTRACT 12/01/2016
GENERAL MTRS CORP	DEB SR CV C ESCROW
GENERAL MTRS CORP	DEB SR CONV B ESCROW
GSCBDRBT INDEX TRS	GS CUSTOM DRBT
HAL 01/20/17 C60	HALLIBURTON CO
INGRAM MICRO INC-CL	A
INGREDION	INCORPORATED
INVENTIV HEALTH INC	10.0000% 08/15/18
ISHARES NASDAQ	BIOTECHNOLOGY ETF
LIBERTY GLOBAL PLC	LILAC SHS CL C
MYOKARDIA INC	COM
NATERA INC	COM
PINNACLE ENTMT INC	
PNC CAP TR C	VAR RT 06/01/28
PNC PFD FUNDING	VAR RT 03/29/49
PRESS GANEY HLDGS IN	COM
RYL BANK SCOTLAND GR	VAR RT MTN, 03/29/49
SELECT SECTOR SPDR T	SBI CONS DISCR
SPDR SERIES TRUST	S&P BIOTECH
SPDR SERIES TRUST	TOTAL RETURN SWAP
STEWART INFORMATION	SERVICES
SUNESIS PHARMACEUTIC	
SYNGENTA AG	SPONSORED ADR
TEVA PHARMACEUTICAL	INDUSTRIES LTD ADR
TEVA PHARMACEUTICAL	PREFCONV 7% 12/15/18
THERAVANCE BIOPHARMA	3.25% CNV BDS 01/11/
TIVO CORP	
UNITED STATES TREAS	1.5000% 08/15/26
VANGUARD INDEX FDS	REIT ETF
VERSUM MATLS INC	COM

Source: Driehaus Capital Management LLC

The portfolio represents holdings for the Driehaus Event Driven Fund (the "Fund") as of the specified date. The Fund assumes no obligation to update or supplement the holdings to reflect subsequent changes. The holdings posted may not represent current or future portfolio composition or holdings and are subject to change without notice. Information on particular holdings may be withheld if it is in the Fund's best interest to do so. The holdings are unaudited and are provided for general information on the Fund. For more information please contact us at 877-779-0079. For information regarding the Fund's policy for valuation of investments and other significant accounting policies, please refer to the Fund's recent Semi-Annual or Annual financial statements.